DETECTION OF MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIALS

File: 123096_sep96_decls1_0035.txt
Page: 0035
Total Pages: 109

Subject: DETECTION OF MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIALS       

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003203

Folder Title: DETECTION OF MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIALS                                       

Document Number:          1

Folder Seq  #:         21




                                      UNCLASSIFIED







               C. TELERAPY

               Almost all cases of inhalation anthrax where treatment was

           begun after patients were symptomatic have been fatal, regardless

           of treatment. Historically, penicillin has been regarded as the

           treatment of choice, with 2 million units given intravenously every

           2 hours. Tetracycline and erythromycin have been recommended in

           penicillin-sensitive patients. The vast majority of anthrax

           strains are sensitive in vitro to penicillin. However, penicillin-

           resistant strains exist naturally, and one has been recovered from

           a fatal human case. moreover, it is not difficult to induce

           resistance to penicillin, tetracycline, erythromycin, and many

           other antibiotics through laboratory manipulation of organisms.

           All naturally-occurring strains tested to date have been sensitive

           to erythromycin, chloramphenicol, gentamicin, and ciprofloxacin.

           In the current setting, treatment should be instituted at the

           earliest signs of disease with ciprofloxacin (1000 mg initially,

           followed by 750 mg bid) or doxycycline (200 mg initially, followed

           by 100 mg q 12 hrs). Supportive therapy for shock, fluid volume

           deficit, and adequacy of airway may all be needed.

               D. PROPEFYLAXIS


               VACCINE

               A licensed, alum-precipitated, preparation of purified

           Bacillus anthracis protective antigen (PA) has been shown to

           be effective in preventing or significantly reducing the



                                         10
                                                                           @Uj@CF-S
                                                      -'L,,.,;3iFIED D@:
                                    UNCLASSIFIED      LILOLPIS@'FY ON: OADR

Document 109 f:/Week-36/BX003203/DETECTION OF MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIALS/detection of medical defense against biological :1217960927452
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = DETECTION OF MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIALS
Folder Seq # = 21
Subject = DETECTION OF MEDICAL DEFENSE AGAINST BIOLOGICAL
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 17-DEC-1996